Lipoatrophy and mitochondrial DNA assays: see all, know all?

This publication has 19 references indexed in Scilit:

• Mitochondrial Effects of HIV Infection on the Peripheral Blood Mononuclear Cells of HIV-Infected Patients Who Were Never Treated with Antiretrovirals
  Clinical Infectious Diseases, 2004
• Changes in Mitochondrial DNA in Peripheral Blood Mononuclear Cells from HIV‐Infected Patients with Lipoatrophy Randomized to Receive Abacavir
  The Journal of Infectious Diseases, 2004
• Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive PatientsA 3-Year Randomized Trial
  JAMA, 2004
• Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir
  AIDS, 2004
• Improvement in Lipoatrophy Associated with Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus–Infected Patients Switched from Stavudine to Abacavir or Zidovudine: The Results of the TARHEEL Study
  Clinical Infectious Diseases, 2004
• Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy
  AIDS, 2003
• Exposure to Dideoxynucleosides Is Reflected in Lowered Mitochondrial DNA in Subcutaneous Fat
  JAIDS Journal of Acquired Immune Deficiency Syndromes, 2002
• Changes in Mitochondrial DNA as a Marker of Nucleoside Toxicity in HIV-Infected Patients
  New England Journal of Medicine, 2002
• Evidence of Nucleoside Analogue Reverse Transcriptase Inhibitor–Associated Genetic and Structural Defects of Mitochondria in Adipose Tissue of HIV-Infected Patients
  JAIDS Journal of Acquired Immune Deficiency Syndromes, 2002
• Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
  The Lancet, 1999